MRI of bone tumors: Fast STIR imaging as a substitute for T1‐weighted contrast‐enhanced fat‐suppressed spin‐echo imaging

Tokuda, Osamu; Hayashi, Noriko; Matsunaga, Naofumi

doi:10.1002/jmri.20031

Cited by 26 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, advances in MR technology as well as improved soft tissue contrast and anatomical resolution on high field MR scanners give rise to the question if the administration of contrast agents is actually always needed. Tokuda and colleagues recently reported comparable results for differentiation of benign from malignant tumors in soft tissue masses (17) and even better results for differentiation of benign from malignant bone tumors by using fast short tau inversion recover (STIR) imaging (18) suggesting that contrast enhancement is not always needed. In addition diffusion weighted MR imaging provides information about solid and cystic/necrotic tumor areas, which was previously only accessible with contrast-enhanced sequences (19).…”

Section: Discussionmentioning

confidence: 99%

Progressing Toward a Cohesive Pediatric ¹⁸F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

et al. 2015

View full text Add to dashboard Cite

With the increasing availability of integrated PET/MR scans the utility and need for MR contrast agents for combined scans is questioned. The purpose of our study was to evaluate if the administration of gadolinium chelates is necessary for evaluation of pediatric tumors on 18F-FDG-PET/MR scans. Methods First, we compared the diagnostic accuracy of pre-contrast T2-weighted fast spin echo (FSE), diffusion-weighted imaging (DWI) and T1-weighted MR scans with post-contrast gadolinium chelate enhanced T1-weighted MR scans for the evaluation of 14 diagnostic criteria in 119 pediatric patients with primary and secondary tumors. We next fused 18F-FDG PET scans with either unenhanced T2-weighted MR scans or gadolinium chelate enhanced T1-weighted MR scans in a subset of 36 pediatric patients. We compared the same 14 diagnostic criteria between fused 18F-FDG PET/T2-FSE and fused 18F-FDG PET/Gd-LAVA scans of 123 tumors in this subgroup and evaluated the concordance or discordance of 18F-FDG PET and gadolinium chelate enhancement, using McNemar’s test. Histopathology, surgical notes and follow up imaging served as the standard of reference. Results Pre- and post-contrast MR scans did not show significant differences in diagnostic accuracies of 14 diagnostic criteria that evaluated image quality and tumor origin, extent, composition and differential diagnosis. Accordingly, there was no significant difference in diagnostic accuracy of integrated 18F-FDG PET/T2-FSE and 18F-FDG PET/Gd-LAVA scans. The 18F-FDG PET/MR subgroup showed concordant gadolinium chelate enhancement and 18F-FDG avidity in 30 of 36 patients and 106 of 123 tumors. Conclusion Gadolinium chelate contrast administration is not necessary for accurate diagnostic characterization of most solid pediatric malignancies on integrated 18F-FDG-PET/MR scans. Exceptions may include focal liver lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Progressing Toward a Cohesive Pediatric ¹⁸F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Gd-DTPA shortens the T1 relaxation time in tumors, causing an increase in signal intensity in vascular regions versus necrotic regions and normal tissue [39]. However, Gd-DTPA is not routinely used for imaging of bone metastases and due to the additional scan time required, was not included in this study.…”

Section: T2 Mr Imaging Demonstrates Tumor Associated Bone Destructionmentioning

confidence: 91%

MRI Detection of Early Bone Metastases in B16 Mouse Melanoma Models

Gauvain

Garbow

Song

et al. 2005

Clin Exp Metastasis

View full text Add to dashboard Cite

Bone metastasis causes significant morbidity in cancer patients, including bone pain, pathologic fractures, nerve compression syndrome, and hypercalcemia. Animal models are utilized to study the pathogenesis of skeletal metastases and to evaluate potential therapeutic agents. Previously published methods for imaging bone metastasis in rodent models have focused on identifying advanced stage metastasis using simple X-rays. Here we report MRI as a method for detecting early bone metastases in mouse models in vivo. B16 mouse melanoma cells were injected into the left cardiac ventricle of C57BL/6 mice and magnetic resonance (MR) images were obtained of the left leg following the development of metastatic disease, when tumor associated bone destruction was histologically present but not visible by X-ray. T1 and T2 relaxation times of bone marrow were measured in healthy control mice and B16 melanoma tumor-bearing mice. Mean T2 values for normal marrow were 28 ms (SD 5) and for diseased bone marrow were 41 ms (SD 3). T2 relaxation time of diseased bone marrow is significantly longer than that of normal bone marrow (P < 0.0001) and can be used as a marker of early bone metastases. These studies demonstrate that MR imaging can detect bone marrow metastases in small animals prior to development of cortical bone loss identified by X-ray.

show abstract

“…PET is therefore considered superior to bone scintigraphy for the detection of bone metastases. Currently, MR imaging with the use of various sequences such as T1-weighted SE or turbo SE imaging, T2-weighted turbo SE imaging, STIR turbo SE imaging, contrastenhanced T1-weighted SE or turbo SE imaging, or diffusion-weighted MR imaging is deemed useful for assessment of muscle-skeletal tumors and metastasis from various malignancies (Weinberger et al 1995;Vanel et al 1998;Mentzel et al 2004;Park et al 2004;Tokuda et al 2004;Goo et al 2005). However, only one study has directly compared the diagnostic capability of MR imaging and bone scintigraphy and found that sensitivity, specificity and accuracy of MR imaging were 80%, 96% and 93%, respectively, being superior to bone scintigraphy (40%, 92%, and 83%), although the difference was not significant (Earnest et al 1999).…”

Section: Bone Metastasismentioning

confidence: 99%

Lung Cancer

Ohno¹,

Koyama²,

Dinkel³

2016

MRI of the Lung

View full text Add to dashboard Cite

Since the publication of the Radiologic Diagnostic Oncology Group Report (RDOG) in 1991, the clinical application of pulmonary magnetic resonance (MR) imaging to patients with lung cancer has been limited. MDCT has been much more widely available for staging of lung cancer in clinical situations. Traditionally, FDG-PET or PET/CT is the only modality that reveals biological glucose metabolism of lung cancer, and ventilation and/or perfusion scintigraphy is the only modality that demonstrates pulmonary function. However, recent advances of MR systems and utilization of contrast media make it possible to overcome the limitation of chest MR imaging. Therefore, in the last years, several investigators have demonstrated the significant comprehensive potential of MR imaging to substitute for MDCT and nuclear medicine examinations in lung cancer staging. Currently, MR imaging in lung cancer patients can be applied for (1) detection of pulmonary nodules, (2) characterization of solitary pulmonary nodules, and (3) assessment of TNM classification in routine clinical practice. We believe that further basic studies, as well as clinical applications of newer MR techniques, will play an important role in the future management of patients with lung cancer including MRI.

show abstract

MRI of bone tumors: Fast STIR imaging as a substitute for T1‐weighted contrast‐enhanced fat‐suppressed spin‐echo imaging

Cited by 26 publications

References 33 publications

Progressing Toward a Cohesive Pediatric ¹⁸F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

Progressing Toward a Cohesive Pediatric ¹⁸F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

MRI Detection of Early Bone Metastases in B16 Mouse Melanoma Models

Lung Cancer

Contact Info

Product

Resources

About

MRI of bone tumors: Fast STIR imaging as a substitute for T1‐weighted contrast‐enhanced fat‐suppressed spin‐echo imaging

Cited by 26 publications

References 33 publications

Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

MRI Detection of Early Bone Metastases in B16 Mouse Melanoma Models

Lung Cancer

Contact Info

Product

Resources

About

Progressing Toward a Cohesive Pediatric ¹⁸F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

Progressing Toward a Cohesive Pediatric ¹⁸F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?